You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Can Sudden Infant Death Syndrome Be Screened With Chromosomic Testing?

  • Authors: News Author: Heidi Splete; CME Author: Charles P. Vega, MD
  • CME / CE Released: 2/3/2023
  • Valid for credit through: 2/3/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Physician Assistant - 0.25 AAPA hour(s) of Category I credit

    IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for primary care physicians, obstetrician gynecologists, pediatricians, and other clinicians who care for children at risk for sudden unexplained death in pediatrics.

The goal of this activity is for learners to be better able to evaluate the genetic profile of children with sudden unexplained death in pediatrics.

Upon completion of this activity, participants will:

  • Analyze risk factors for sudden infant death syndrome
  • Evaluate the genetic profile of children with sudden unexplained death in pediatrics
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Heidi Splete

    Freelance writer, Medscape

    Disclosures

    Heidi Splete has no relevant financial relationships.

CME Author

  • Charles P. Vega, MD

    Health Sciences Clinical Professor of Family Medicine
    University of California, Irvine School of Medicine

    Disclosures

    Charles P. Vega, MD, has the following relevant financial relationships:
    Consultant or advisor for: GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Editor/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 02/03/2024. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Can Sudden Infant Death Syndrome Be Screened With Chromosomic Testing?

Authors: News Author: Heidi Splete; CME Author: Charles P. Vega, MDFaculty and Disclosures

CME / CE Released: 2/3/2023

Valid for credit through: 2/3/2024, 11:59 PM EST

processing....

Clinical Context

Sudden infant death syndrome (SIDS) and sudden unexplained death in children (SUDC) are both defined by sudden unexpected, unexplained death however, SIDS refers to children younger than one year and SUDC refers to a children greater than one year old. Although the rate of SIDS in the US has declined in the past several decades, the prevalence of SIDS remains approximately twice as high among Black and American Indian/Alaska Native populations. In a previous review article by Adams and colleagues published in the June 1, 2015, issue of the American Family Physician, risk factors for SIDS were outlined.[1] They found that the most important risk factors for SIDS involve the sleep environment; sleeping position, bed sharing, soft bedding and use of car seats for sleep. In addition, mental illness in either parent was associated with a higher risk for SIDS. A new study suggests there may be a genetic component to SIDs and SUDC.

Study Synopsis and Perspective

Researchers have identified pathogenic gene variations in 12% of cases of SUDC.

The new study, which involved 116 cases of SIDS or SUDC, suggests that available methods of chromosome testing could be used to help screen for the conditions, which together account for roughly 1800 fatalities a year in the United States.

“Even though the Back to Sleep campaign has been incredibly effective and safe sleep practices have been promoted for years, sudden unexplained death in pediatrics remains a leading cause of death for infants and children,” said Catherine Brownstein, MPH, PhD, from Boston Children’s Hospital in Massachusetts, lead author of the new study.[2]

The findings suggest that chromosomal microarray analysis (CMA), the method that the researchers used in the study, “should be considered in the genetic evaluation of SUDC,” Dr Brownstein said. The approach is the first-line method of identifying conditions such as autism spectrum disorder (ASD), developmental disabilities, multiple congenital anomalies, and epilepsy, she noted.

In the study, published in Advanced Genetics, Dr Brownstein and colleagues used CMA to test genes from 116 deceased infants and toddlers up to age 28 months whose deaths were classified as SIDS or SUDC (the latter term applies to children older than 1 year).

The average age at the time of death was 5.7 months; 59% of the patients were boys. In 14 of the children (12%), the CMA test identified genetic variations in the form of deletions or duplications that were pathogenic (5 cases) or uncertain but “favoring pathogenicity” (9 cases). Such deletions or duplications are known as copy number variants (CNVs).

CNVs are present in most people and are not necessarily associated with disease, according to the researchers. However, certain CNVs have been linked to ASD, attention-deficit/hyperactivity disorder, schizophrenia, Crohn’s disease, epilepsy, and various congenital abnormalities.

Dr Brownstein’s group also compared pathogenicity in the SUDC group with that of a cohort of children with ASD and with healthy control persons. They found no significant difference in pathogenicity between SUDC and autism with regard to duplications. However, children in the SUDC group were significantly more likely to have higher pathogenicity scores for deletions compared with control persons. Some of the CMVs did not appear connected to SIDS or SUDC; 2 cases in boys were undiagnosed cases of Klinefelter syndrome.

The study findings were limited by several factors, including the small sample size and the inability to conduct CMA analyses on parents or obtain family history, the researchers note. Other limitations were that phenotypic data were available only from autopsy material and medical records and that the study focused on younger children, the researchers add. They did not speculate about the causes of deaths in the other cases that they examined.

Findings Support Clinical Value of CMA

In the current study, the other 88% of cases could involve nongenetic factors or genetic factors that are not measured by next-generation sequencing or chromosomal microarray, Dr Brownstein said. “Undiagnosed disease programs looking for genetic causes for diseases in living patients identify a cause in about 1 in 4 cases,” she said. “While 12% is a modest percentage, the CNVs identified provide additional information. In the future, the goal would be to capture the full range of potential genetic changes.”

Previous research by Dr Brownstein’s group at Robert’s Program, a clinical service for SUDC families at Boston Children’s Hospital, found genetic variants that might cause sudden death in children.

“We began this study with the simple question of whether, as a population, these children carry more copy number variation, which they do,” she said. “However, none of the CMA findings we identified are currently associated with SUDC, so much more investigation is necessary to find out if they are coincidental, risk factors, or causative.”

Looking ahead, she said, “Ideally, we would want every family affected by sudden unexplained death in pediatrics to have genetic testing, including a chromosomal microarray. Once we have more families enrolled and tested, we will be able to understand the risk factors for SIDS and SUDC much better.”

Benjamin Solomon, MD, clinical director at the National Human Genome Research Institute, said that the new research “may bring answers for individual situations, as well as enable research to understand the overall biological underpinnings and causes of disease.”

The findings “help reinforce the heterogeneous nature of SUDC and related conditions,” Dr Solomon said. “The results also highlight some of the challenges regarding how to interpret the possible clinical effects of genetic changes. That is, every person has genetic changes, and interpreting how certain genetic changes may or may not contribute to a disease or healthcare outcome can be challenging.”

Research is needed to understand not only the overall causes of SUDC but also how the different causes interact, Dr Solomon said. “Eventually, better understanding of the causes could lead to knowledge that would enable interventions that could help prevent or reduce these devastating outcomes.”

The study was supported by the Robert’s Program on Sudden Unexplained Death in Pediatrics, the Jude Zayac Foundation, multiple grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institutes of Health, the Boston Children’s Hospital Intellectual and the Developmental Disabilities Research Center Molecular Genetics Core Facility (supported by the National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development), and the National Institute of Mental Health/National Institutes of Health. The researchers and Dr Solomon have disclosed no relevant financial relationships.

Adv Genet. Published online November 7, 2022.

Study Highlights

  • Cases were drawn from databases from San Diego, California, and Boston, Massachusetts. These databases contained demographic information on the children who died, as well as medical history.
  • CNVs were classified as pathogenic, likely pathogenic, or variant of uncertain significance through comparisons with multiple genetic databases. Researchers sought to determine whether CNVs associated with SUDP could be linked to other disease states.
  • Researchers also compared the results from SUDP cases with healthy controls.
  • 116 cases of SUDP were included in the study cohort; 59% of cases were boys, and the average age at death was 5.7 months.
  • The average gestational age of SUDP cases was 38.3 weeks, and 30% of cases were cosleeping with others at the time of death. A total of 43% of cases were found in the prone position at the time of death.
  • 78% of the cohort had at least 1 CNV; 18% of SUDP cases had a CNV greater than 1 Mb in size.
  • 4.3% of SUDP cases had a CNV categorized as pathogenic or likely pathogenic and linked to a known disease. These CNVs were associated with a number of neuropsychological disorders, including autism spectrum disorder, schizophrenia, spinal muscular atrophy, and deafness. Other CNVs discovered in SUDP cases were associated with short stature and male infertility. Of note, none of these disorders was clinically evident at the time of death in SUDP cases.
  • 7.8% of SUDP cases had a CNV of unknown significance but favoring pathogenic. Several of these CNVs were also associated with neuropsychological disorders.
  • 3 cases (2 boys and 1 girl) had chromosomal microarray abnormalities involving the X chromosome. The 2 boys had the XXY karyotype consistent with Klinefelter syndrome.
  • Variants of unknown significance were identified in 46% of cases.
  • The odds ratio for pathological CNVs in comparing cases of SUDP with healthy controls was 1.24 (95% CI, 1.11-1.31).

Clinical Implications

  • Although the rate of SIDS in the US has declined in the past several decades, the prevalence of SIDS remains approximately twice as high among Black and American Indian/Alaska Native populations. The most important risk factors for SIDS involve the sleep environment. The use of car seats for sleep and soft bedding materials also increases the risk for SIDS. Mental illness in either parent is associated with a higher risk for SIDS.
  • 4.3% of SUDP cases in the current study had a CNV categorized as pathogenic or likely pathogenic and linked to a known disease. These CNVs were associated with a number of neuropsychological disorders, including autism spectrum disorder, schizophrenia, spinal muscular atrophy, and deafness. The odds ratio for pathological CNVs in comparing cases of SUDP with healthy controls was 1.24.
  • Implications for the healthcare team: When counseling parents regarding the risk for SUDP, the healthcare team should consider family history and possible genetic implications.

 

Earn Credit

  • Print